BioNTech (Germany) Top Insiders
| 22UA Stock | EUR 111.40 1.00 0.89% |
BioNTech employs about 4 K people. The company is managed by 9 executives with a total tenure of roughly 9334 years, averaging almost 1037.0 years of service per executive, having 444.44 employees per reported executive. Examination of BioNTech's management performance can provide insight into the company performance.
| Jens Holstein Insider CFO Board |
| Sylke Maas Insider VP Strategy |
BioNTech |
BioNTech Management Team Effectiveness
The company has return on total asset (ROA) of 0.4283 % which means that it generated a profit of $0.4283 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.7624 %, meaning that it generated $0.7624 on every $100 dollars invested by stockholders. BioNTech's management efficiency ratios could be used to measure how well BioNTech manages its routine affairs as well as how well it operates its assets and liabilities.BioNTech Workforce Comparison
BioNTech SE is number one stock in number of employees category among its peers. The total workforce of Biotechnology industry is presently estimated at about 297,538. BioNTech claims roughly 4,000 in number of employees contributing just under 2% to stocks in Biotechnology industry.
The company has Profit Margin (PM) of 0.56 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.68 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.68. BioNTech SE Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. BioNTech SE Price Series Summation is a cross summation of BioNTech price series and its benchmark/peer.
BioNTech Notable Stakeholders
A BioNTech stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as BioNTech often face trade-offs trying to please all of them. BioNTech's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting BioNTech's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Pr MD | CoFounder Board | Profile | |
| Jens Holstein | CFO Board | Profile | |
| Sylke Maas | VP Strategy | Profile | |
| James Ryan | Sr Counsel | Profile | |
| Michael Boehler | MD Communications | Profile | |
| Ryan Richardson | MD Officer | Profile | |
| Sierk Poetting | COO MD | Profile | |
| Ozlem MD | Chief CoFounder | Profile | |
| Sean Marett | Chief Officer | Profile |
About BioNTech Management Performance
The success or failure of an entity such as BioNTech SE often depends on how effective the management is. BioNTech management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of BioNTech management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the BioNTech management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany. BIONTECH operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 2500 people.
BioNTech Workforce Analysis
Traditionally, organizations such as BioNTech use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare BioNTech within its industry.BioNTech Manpower Efficiency
Return on BioNTech Manpower
| Revenue Per Employee | 4.7M | |
| Revenue Per Executive | 2.1B | |
| Net Income Per Employee | 2.6M | |
| Net Income Per Executive | 1.1B |
Complementary Tools for BioNTech Stock analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |